Utrecht, the Netherlands, October 29th, 2009 – Podiceps BV, a Dutch private company that discovers, develops and commercializes novel biomarkers and clinical targets based in Utrecht, has received a subsidy of 36.000 euro  from the ISH programme (www.senternovem.nl) to explore an antibody-based method based on the nuclear organization in cancer cells. In collaboration with the University Utrecht and the company Bioceros (www.bioceros.coml) Podiceps will examine the POC to develop an automated biomarker assay for cancer cells based on the difference in nuclear organization.

 

 


Latest News

Podiceps receives Innovation Subsidy

Utrecht, the Netherlands, October 29th, 2009 – Podiceps BV, a Dutch private company that discovers, develops and commercializes novel biomarkers and [...] read on...

Podiceps closes development and license agreement

Utrecht, the Netherlands, January 31st, 2007 – Podiceps BV, a Dutch private company that discovers, develops and commercializes novel biomarkers and [...] read on...